



Original Article

# Concomitant transrectal ultrasound-guided biopsy and transurethral resection of prostate in patients with urinary retention and elevated serum prostate-specific antigen levels

Ti-Yuan Yang<sup>a,b</sup>, Yung-Chiong Chow<sup>a,b,\*</sup>, Wun-Rong Lin<sup>a,b</sup>, Ming-Chung Ko<sup>c</sup>, Marcelo Chen<sup>a,b</sup>, Huang-Kuang Chang<sup>a,b</sup>, Jong-Ming Hsu<sup>a,b</sup>, Stone Yang<sup>a,b</sup>, Wen-Chou Lin<sup>a,b</sup>, Allen W. Chiu<sup>a,b,d</sup>

<sup>a</sup> Department of Urology, Mackay Memorial Hospital, Taipei, Taiwan, ROC

<sup>b</sup> Department of Medicine, Mackay Medical College, Taipei, Taiwan, ROC

<sup>c</sup> Taipei City Hospital, Taipei, Taiwan, ROC

<sup>d</sup> Department of Urology, School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC

Received October 22, 2015; accepted February 21, 2016

## Abstract

**Background:** There was no consensus about the management of patients with urinary retention and elevated serum prostate-specific antigen (PSA) levels. This study aimed to determine whether concomitant transrectal ultrasound (TRUS)-guided biopsy and transurethral resection of prostate (TURP) is practical in patients with urinary retention and elevated serum PSA levels.

**Methods:** From March 2007 to May 2015, a total of 34 patients with urinary retention and elevated PSA ( $\geq 4$  ng/mL) underwent concomitant TRUS-guided biopsy and TURP. The medical records were evaluated retrospectively, and data including PSA, prostate volume, TURP results, TRUS-guided biopsy results, length of hospitalization, and complications were collected. These patients were then compared with 40 patients with urinary retention who underwent TURP alone.

**Results:** The mean age of the patients was 71.6 years. The mean PSA levels were 16.9 ng/mL. Prostate cancer was detected in eight cases (23.5%): one case by TRUS-guided biopsy alone, two cases by TURP alone, and five cases by both TRUS-guided biopsy and TURP. Complications included fever in five patients (14.7%), recatheterization for urine retention in two patients (5.9%), urinary tract infection in two patients (5.9%), and *de novo* urge incontinence in seven patients (20.6%). The complication rate was not significantly increased compared with that of the patients who underwent TURP alone.

**Conclusion:** This study showed that concomitant TRUS-guided biopsy and TURP was safe and of possible clinical significance in urinary retention patients with elevated serum PSA.

Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Keywords:** prostate cancer; prostate-specific antigen; transrectal ultrasound-guided biopsy; transurethral resection of prostate; urinary retention

Conflicts of interest: The authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.

\* Corresponding author. Dr. Yung-Chiong Chow, Department of Urology, Mackay Memorial Hospital, 92, Section 2, Zhongshan North Road, Taipei 104, Taiwan, ROC.

E-mail addresses: [urodc@hotmail.com](mailto:urodc@hotmail.com), [4271.4271@mmh.org.tw](mailto:4271.4271@mmh.org.tw) (Y.-C. Chow).

<http://dx.doi.org/10.1016/j.jcma.2016.03.008>

1726-4901/Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Introduction

An increase in serum prostate-specific antigen (PSA) levels in patients with urinary retention has been frequently reported.<sup>1–3</sup> In clinical settings, it is sometimes difficult to determine the cause of PSA elevation. Routine PSA testing before transurethral resection of prostate (TURP) in these patients remains controversial. Some urologists advocate preoperative PSA testing, while others find it unnecessary and

even misleading.<sup>4</sup> In cases with PSA elevation, pre-TURP transrectal ultrasound (TRUS)-guided biopsy carries certain risks, because the biopsy may worsen the urinary retention and may result in complications. Factors influencing the decision of whether or not to perform the biopsy include the patient's age, willingness, health condition, past PSA data, past biopsy results, and the urologist's preferences. The aim of this study was to determine whether concomitant TRUS-guided biopsy and TURP was viable in patients with urinary retention and elevated serum PSA ( $\geq 4$  ng/mL).

## 2. Methods

We retrospectively reviewed patients referred to the urology department for urinary retention from March 2007 to May 2015. Patients older than 80 years and those with serum PSA  $< 4$  ng/mL or PSA  $\geq 100$  ng/mL were excluded from this study. These patients were excluded because the value of prostatic biopsy in this age group was questionable, and serum PSA  $\geq 100$  ng/mL was regarded as an important indicator of metastatic disease. Patients with trauma- or drug-related bladder outlet obstruction, previous bladder or prostate malignancies, acute neurologic conditions, and urosepsis were also excluded. All patients signed an informed consent document before the operation. A total of 34 patients underwent concomitant TRUS-guided prostate biopsy and TURP. Prostate volume was measured by transrectal ultrasound (BK Medical Hawk 2102 EXL; BK Medical, Herlev, Denmark). All patients received bowel preparation with cleansing phosphate enema (Evac enema, 118 mL) the night before surgery and perioperatively were intravenously administered a prophylactic broad-spectrum antibiotic. Under spinal or general anesthesia, the patient was placed in the lithotomy position. A 12-core needle biopsy using an 18-gauge needle biopsy gun (Bard Peripheral Vascular Inc., Tempe, AZ, USA) was performed under transrectal ultrasound guidance. Routine fiberoptic cystoscopy was performed to rule out any unexpected prostatic and bladder lesions. Bipolar TURP (PlasmaKinetic Tissue Management System; Gyrus Medical Ltd., Cardiff, UK) was carried out using the standard procedures. Oral quinolone was given for 5 days. The pathologist examined the resected prostate chips and biopsy specimens separately.

The patients' demographic data, preoperative PSA levels, prostate volume, PSA density, length of hospitalization, length of catheterization, recatheterization rate, postoperative complications, and TURP and biopsy pathological results were recorded. Results were compared to those of a separate cohort of 40 patients with prostate enlargement-related urinary retention who underwent TURP alone during the study period. In these 40 patients, PSA testing was not collected before TURP. The results were compared using an independent *t* test and Fisher's exact test. A *p* value  $< 0.05$  was considered to be statistically significant.

## 3. Results

The mean age of the patients was 71.6 years. The mean PSA levels were 16.9 ng/mL. The mean prostate volume was

60.8 cm<sup>3</sup>. Comparison between patients with cancer and benign prostatic hyperplasia (BPH) showed no statistically significant differences in patients' age, serum PSA levels, prostate volume, and prostate-specific antigen density (PSAD; Table 1).

Overall, prostate cancer was detected in eight cases (23.5%; Table 2); it was detected by both TRUS-guided biopsy and TURP in five cases, by TURP alone in two cases, and by biopsy alone in one case. In the case diagnosed by biopsy alone, the PSA levels were 6.66 ng/mL, adenocarcinoma was found in all 12 cores, and the Gleason score was 5 + 5. The Gleason score was 3 + 3 and 3 + 4 in the two cases detected by TURP alone.

No statistically significant differences in patient age, post-operative fever, recatheterization for urine retention, urge incontinence, urinary tract infection, bladder neck contracture, length of hospitalization, and length of catheterization were found. The cancer detection rate was significantly higher (8/34 vs. 2/40; *p* = 0.023) in the group of concomitant TRUS-guided biopsy and TURP (Table 3).

## 4. Discussion

Urinary retention is the main indication for surgery in approximately one fourth of male patients who undergo TURP.<sup>5</sup> It has been reported that urinary retention increases the serum PSA levels by up to six-fold over the normal limits.<sup>1–3</sup> There is no consensus regarding the standard approach to this condition. Some doctors advocate TURP alone, while others routinely perform preoperative TRUS-guided biopsy. Chen et al<sup>6</sup> reported simultaneous TURP and TRUS-guided biopsy to release acute urinary retention and documented a definite diagnosis. We excluded patients older than 80 years because the value of prostatic biopsy in this age group was questionable, and serum PSA  $\geq 100$  ng/mL was excluded because it was regarded as an important indicator of metastatic disease.<sup>7,8</sup>

The rate of incidental cancer detected by TURP was 22% before PSA testing, and decreased to 9.8% in the past two decades.<sup>9</sup> In our study, prostate cancer was found in eight of 34 patients (23.5%). Most of the cancers (7/8) were found in the TURP chips. However, the one case missed in the TURP chips and detected by concomitant TRUS-guided biopsy was a high-risk cancer (Gleason 5 + 5) with PSA of 6.66 ng/mL. This result stresses the importance of preoperative explanation to the patient. There were no Gleason scores higher than 8 in the TURP chips. This observation also concurs with earlier

Table 1  
Comparison of patients with prostate cancer and BPH.

	All patients	Prostate cancer	BPH	<i>p</i>
No. of patients	<i>n</i> = 34	<i>n</i> = 8	<i>n</i> = 26	
Age (y)	71.6 ± 7.0	74.4 ± 7.3	70.8 ± 6.8	0.209
PSA (ng/mL)	10.9 (5.7–67.1)	12 (7.5–58.4)	10.5 (5.6–55.9)	0.653
Prostate volume (cm <sup>3</sup> )	60.8 ± 32.0	42.3 ± 23.5	66.4 ± 32.6	0.068
PSAD	0.36 ± 0.43	0.66 ± 0.73	0.27 ± 0.23	0.177

BPH = benign prostatic hyperplasia; PSA = prostate-specific antigen; PSAD = prostate-specific antigen density.

Table 2  
Characteristics of patients with prostate cancer.

Patient No.	Age (y)	Prostate volume (cm <sup>3</sup> )	PSA (ng/mL)	PSAD (ng/mL/cm <sup>3</sup> )	Pathological results (Gleason score)	
					TRUS-guided biopsy	TURP
1	71	88.0	7.13	0.08	Negative	3 + 3
2	59	17.8	12.00	0.67	4 + 3	4 + 3
3	79	58.8	6.66	0.11	5 + 5	Negative
4	78	28.9	63.42	2.19	3 + 4	4 + 3
5	79	45.9	9.69	0.21	4 + 3	3 + 3
6	79	53.0	11.98	0.23	Negative	3 + 4
7	70	23.6	30.22	1.28	5 + 3	3 + 5
8	80	26.6	14.24	0.54	4 + 3	3 + 4

PSA = prostate-specific antigen; PSAD = prostate-specific antigen density; TRUS = transrectal ultrasound; TURP = transurethral resection of prostate.

report which indicated that prostate cancers originating in the transitional zone are usually less invasive than those originating in the peripheral zone.<sup>10</sup> In the cohort of 40 patients who underwent TURP alone without testing PSA levels before the operation, the cancer detection rate was 5%. The significantly higher ( $p = 0.023$ ) cancer detection rate can be explained by the following factors: patients in the group of concomitant TRUS-guided biopsy and TURP had elevated PSA levels, however, the PSA level was not checked in the other 40 patients, resulting in an unknown ratio of elevated- to normal-PSA levels. The higher cancer detection rate can also be attributed to TRUS-guided biopsy, which was obtained from the peripheral zone tissue.

The patients we enrolled into the study underwent prostate ultrasound after Foley catheterization for acute urinary

retention. The measurement of prostate volume was influenced by the catheter and inflammation. In addition, urinary retention increases the serum PSA level with a wide range from two- to six-fold.<sup>1,2</sup> Comparison between patients with cancer and BPH showed no statistically significant differences in PSAD. Hence, we consider that PSAD is not a reliable cancer predictor for patients with acute urinary retention.

Present-day complications of TURP are relatively minor owing to improved technologies such as surgical devices and imaging systems. Concomitant TRUS-guided biopsy and TURP is safe, as shown in our study. The incidence of urinary tract infection (UTI) after TRUS-guided biopsy ranges between 2% and 6%, and bacteremia was reported in ~30–50% of these patients.<sup>11</sup> Nam et al<sup>12</sup> reported that the rate of readmission within 30 days was 4.1% in patients who underwent TRUS-guided biopsy, with infection as the main cause. UTI occurred in 1.7–14.0% of patients after TURP.<sup>13</sup> Due to urinary retention and urethral catheterization, we used an extended course of oral antibiotics to prevent postoperative UTI. In our study, postoperative fever occurred in five patients (14.3%), whereas two patients (5.7%) were readmitted due to UTI confirmed by urine culture and bacteremia confirmed by blood culture. In contemporary studies, the rate of urinary retention post-TURP has been reported to be from 3% to 9.9% and the rate of temporary urge incontinence was 30–40%.<sup>13,14</sup> By comparison, 5.9% of our patients suffered from transient urinary retention, while 20.6% patients complained of temporary urge incontinence. Two recatheterized patients voided successfully, and the incidence of *de novo* urge incontinence declined to 2.9% after 6 months. Major late complications of

Table 3  
Comparisons of complications and cancer detection rate between TURP alone and concomitant TRUS-guided biopsy and TURP.

	All patients $n = 74$	TURP $n = 40$	Concomitant TRUS-guided biopsy and TURP $n = 34$	$p$
Age (y)	71.1 ± 6.7	70.7 ± 6.4	71.6 ± 7.0	0.548
Underlying disease				
Hypertension	26	16	10	0.241
Diabetes mellitus	13	8	5	0.388
Coronary artery disease	5	1	4	0.132
Hyperlipidemia	3	2	1	0.561
Chronic kidney disease	1	0	1	0.460
Cerebrovascular accident	8	2	6	0.085
Congestive heart failure	2	1	1	0.711
Pulmonary tuberculosis	1	0	1	0.460
COPD	2	1	1	0.711
Asthma	2	1	1	0.711
Liver cirrhosis	1	1	0	0.541
Urolithiasis	8	3	5	0.268
Urge incontinence	15 (20.3)	8 (20)	7 (20.6)	0.588
Urinary retention	10 (13.5)	8 (20)	2 (5.9)	0.074
Fever	7 (9.5)	2 (5.0)	5 (14.7)	0.153
Urinary tract infection	2 (2.7)	0 (0)	2 (5.9)	0.208
Bladder neck contracture	2 (2.7)	1 (2.5)	1 (2.9)	0.711
Length of catheterization (d)	3 (2.0–16.8)	3 (2.0–25.9)	3 (1.8–10.5)	0.130
Length of hospitalization (d)	3.9 ± 1.5	4.0 ± 1.2	3.9 ± 1.8	0.911
Cancer	10 (13.5)	2 (5.0)	8 (23.5)	0.023*

Data are presented as  $n$ ,  $n$  (%),  $n$  (range), or mean ± standard deviation.

\* A  $p$  value < 0.05 is statistically significant.

COPD = chronic obstructive pulmonary disease; TURP = transurethral resection of prostate; TRUS = transrectal ultrasound.

TURP include urethral stricture (range, 2.2–9.8%) and bladder neck contracture (range, 0.3–9.2%).<sup>13</sup> Only one patient in our study had bladder neck contracture at 14 months and remained symptom-free after undergoing bladder neck incision. Comparison with a cohort of patients who underwent TURP alone, revealed no statistically significant differences in patient age, postoperative fever, UTI, bladder neck contracture, recatheterization rate, urge incontinence, length of hospitalization, and length of catheterization (Table 3). This result attests to the safety of concomitant TRUS-guided biopsy and TURP in urinary retention patients.

A potential disadvantage of concomitant TURP and TRUS-guided biopsy concerns patients with prostate cancer who are suitable candidates for radical prostatectomy. Previous studies showed that patients with a history of TURP had poorer outcomes after laparoscopic radical prostatectomy, and previous TURP also presented a challenge to surgeons during robot-assisted radical prostatectomy.<sup>15,16</sup> However, other studies reported that although the procedure is technically more demanding, when performed by expert surgeons, the overall urinary function outcomes and frequency of positive surgical margins appear to be similar.<sup>17–21</sup>

Urodynamic studies were not performed in our patients prior to surgery. Previous studies showed that even if preoperative urodynamic exams in urinary retention patients suggested an unfavorable outcome, especially in those younger than 80 years, most could void by themselves without catheterization at 3 months post-TURP.<sup>22,23</sup> Two of our patients with temporary urinary retention requiring recatheterization voided successfully 1 month post-TURP.

Limitations of our study include small sample size, varying source of patients' referrals, and the retrospective nature of the study. There were potential study biases in that many patients were referred from other clinics and the interval between PSA examination and acute urinary retention episode varies. Further prospective multi-center studies with a larger sample size are required to provide future guidelines for this controversial clinical issue.

In conclusion, this study revealed the safety and value of concomitant TRUS-guided biopsy and TURP in urinary retention patients with elevated serum PSA. Concomitant TRUS-guided biopsy is a viable option during TURP for patients with urinary retention and elevated serum PSA.

## References

- Pruthi RS. The dynamics of prostate-specific antigen in benign and malignant diseases of the prostate. *BJU Int* 2000;**86**:652–8.
- Aliasgari M, Soleimani M, Hosseini Moghaddam SM. The effect of acute urinary retention on serum prostate-specific antigen level. *Urol J* 2005;**2**: 89–92.
- Kalejaiye O, Speakman MJ. Management of acute and chronic retention in men. *European Urology Supplements* 2009;**8**:523–9.
- Manikandan R, Srirangam SJ, O'Reilly PH, Collins GN. Management of acute urinary retention secondary to benign prostatic hyperplasia in the UK: a national survey. *BJU international* 2004;**93**:84–8.
- Mayer EK, Kroeze SG, Chopra S, Bottle A, Patel A. Examining the 'gold standard': a comparative critical analysis of three consecutive decades of monopolar transurethral resection of the prostate (TURP) outcomes. *BJU Int* 2012;**110**:1595–601.
- Chen YT, Chiang PH, Hsu CC. Simultaneous transurethral resection of prostate and prostate needle biopsy in patients with acute urinary retention and elevated prostate specific antigen levels. *Chang Gung Med J* 2009;**32**: 417–22.
- Bott SR, Foley CL, Bull MD, Reddy CC, Freeman A, Montgomery BS, et al. Are prostatic biopsies necessary in men aged > or = 80 years? *BJU Int* 2007;**99**:335–8.
- Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. *Eur Urol* 2014;**65**:124–37.
- Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. *J Urol* 2008;**180**:246–9.
- Erbersdobler A, Fritz H, Schnoger S, Graefen M, Hammerer P, Huland H, et al. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. *Eur Urol* 2002; **41**:40–6.
- Williamson DA, Barrett LK, Rogers BA, Freeman JT, Hadway P, Paterson DL. Infectious complications following transrectal ultrasound-guided prostate biopsy: new challenges in the era of multidrug-resistant *Escherichia coli*. *Clin Infect Dis* 2013;**57**:267–74.
- Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. *J Urol* 2010;**183**:963–8.
- Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP): incidence, management, and prevention. *Eur Urol* 2006;**50**:969–79.
- Ahyai SA, Gilling P, Kaplan SA, Kuntz RM, Madersbacher S, Montorsi F, et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. *Eur Urol* 2010;**58**:384–97.
- Jaffe J, Stakhovskiy O, Cathelineau X, Barret E, Vallancien G, Rozet F. Surgical outcomes for men undergoing laparoscopic radical prostatectomy after transurethral resection of the prostate. *J Urol* 2007;**178**:483–7.
- Montorsi F, Wilson TG, Rosen RC, Ahlering TE, Artibani W, Carroll PR, et al. Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. *Eur Urol* 2012;**62**: 368–81.
- Gacci M, Simonato A, Lanciotti M, Ennas M, Varca V, Maffezzini M, et al. The impact of prior TURP on radical prostatectomy surgical margins: a multicenter analysis. *Urol Int* 2013;**91**:62–8.
- Springer C, Inferrera A, Pini G, Mohammed N, Fornara P, Greco F. Laparoscopic versus open bilateral intrafascial nerve-sparing radical prostatectomy after TUR-P for incidental prostate cancer: surgical outcomes and effect on postoperative urinary continence and sexual potency. *World J Urol* 2013;**31**:1505–10.
- Gellhaus PT, Monn MF, Leese J, Flack CK, Lingeman JE, Koch MO, et al. Robot-assisted radical prostatectomy in patients with a history of holmium laser enucleation of the prostate: feasibility and evaluation of initial outcomes. *J Endourol* 2015;**29**:764–9.
- Zugor V, Labanaris AP, Porres D, Witt JH. Surgical, oncologic, and short-term functional outcomes in patients undergoing robot-assisted prostatectomy after previous transurethral resection of the prostate. *J Endourol* 2012;**26**:515–9.
- Su YK, Katz B, Sehgal S, Yu SJ, Su YC, Lightfoot A, et al. Does previous transurethral prostate surgery affect oncologic and continence outcomes after RARP? *J Robotic Surg* 2015;**9**:291–7.
- Radomski SB, Herschorn S, Naglie G. Acute urinary retention in men: a comparison of voiding and nonvoiding patients after prostatectomy. *J Urol* 1995;**153**:685–8.
- Djavan B, Madersbacher S, Klingler C, Marberger M. Urodynamic assessment of patients with acute urinary retention: Is treatment failure after prostatectomy predictable? *J Urol* 1997;**158**:1829–33.